Spruce Biosciences Resumes Trading on the Nasdaq Capital Market
News > Business News
Audio By Carbonatix
4:00 AM on Monday, September 15
The Associated Press
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sep 15, 2025--
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that it will resume trading on the Nasdaq Capital Market at the market open today, September 15, 2025, under the ticker symbol “SPRB” and CUSIP 85209E 208.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook and YouTube.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250915439985/en/
CONTACT: Spruce Media
Katie Beach Oltsik
Inizio Evoke Comms
(937) 232-4889
[email protected] Investors
Samir Gharib
President and CFO
Spruce Biosciences, Inc.
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH
SOURCE: Spruce Biosciences, Inc.
Copyright Business Wire 2025.
PUB: 09/15/2025 07:00 AM/DISC: 09/15/2025 06:59 AM
http://www.businesswire.com/news/home/20250915439985/en
